Long-term follow-up of a patient with 5q31.3 microdeletion syndrome and the smallest de novo 5q31.2q31.3 deletion involving PURA by Maria Clara Bonaglia et al.
CASE REPORT Open Access
Long-term follow-up of a patient with
5q31.3 microdeletion syndrome and the
smallest de novo 5q31.2q31.3 deletion
involving PURA
Maria Clara Bonaglia1*, Nicoletta Zanotta2, Roberto Giorda3, Grazia D’Angelo4 and Claudio Zucca2
Abstract
Background: Purine-rich element binding protein A (PURA, MIM 600473), is considered the crucial phenocritical
gene for an emerging 5q31.3 microdeletion syndrome. To date, at least seven affected individuals with overlapping
5q31.2q31.3 deletions, varying in size from 2.6 to 5 Mb, have been reported sharing neurologic features such as severe
developmental delay, neonatal hypotonia, early feeding difficulties, respiratory distress and EEG abnormalities.
The recent finding that de novo PURA point mutations are indeed sufficient to cause the severe neurological
symptoms also observed in patients with 5q31.2q31.3 deletion further reinforces the gene’s causative role in
5q31.3 microdeletion syndrome.
Case presentation: The present patient, aged 26 years, is the oldest reported individual and carries the smallest de
novo 5q31.2q31.3 microdeletion encompassing PURA (360 kb). Her clinical history summarizes the mainly
neurodevelopmental phenotype described in children with 5q31.3 microdeletion syndrome. In addition, our
patient exhibited a remarkable deterioration of clinical symptoms, starting at the beginning of adolescence,
pubertal delay and primary amenorrhea. While epileptic seizures were successfully treated during her life,
feeding problems showed a poor outcome, her respiratory problems increased and eventually became severe
enough to cause her death.
Conclusion: The clinical and molecular findings reported here provide further evidence that 5q31.3
microdeletion syndrome is a clinically discernible PURA-related disorder and describe the previously
unreported natural evolution of the disease in a 26 years old patient.
Keywords: 5q31.3 microdeletion syndrome, Array-CGH, Neurodevelopmental phenotype, PURA gene,
5q31.2q31.3 deletion
Background
The 5q31.3 microdeletion syndrome is an emerging con-
dition characterized by severe developmental delay, neo-
natal hypotonia, early feeding difficulties, early-onset
seizures, respiratory distress and neuroimaging abnor-
malities [1–4]. To date at least seven affected children
carrying 5q31.2q31.3 deletions, varying in size from 2.6
to 5 Mb, have been reported [1–4].
The minimal deletion region of ~101 Kb [5] between
all published patients [1–4] harbors three genes: purine-
rich element binding protein A (PURA), IgA-inducing
protein (IGIP,) and cysteine-rich transmembrane module
containing 1 (CYSTM1) [3]. PURA, encoding activator
protein Pur- α (MIM 600473), has been proposed as the
phenocritical gene [1] based on its role in neuronal de-
velopment [6, 7]. The recent finding that de novo PURA
point mutations are indeed sufficient to cause the same
severe neurological symptoms observed in patients with
5q31.3 deletion further reinforces PURA’s causative role
in 5q31.3 microdeletion syndrome [5, 8]. The present
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patient, aged 26 years, is the oldest reported individual
and carries the smallest de novo 5q31.2q31.3 microdele-
tion encompassing PURA (360 kb). To our knowledge,
this is the first report of the longitudinal medical history
of a patient with PURA-related disorder.
Case presentation
The proband is a female (Fig. 1a–f ), the third child of
healthy non-consanguineous parents aged 38 (father)
and 34 (mother) years at her birth. Delivery was at
40 weeks of gestation. Birth weight was 3700 g. Length,
OFC and Apgar scores were not available. At birth she
was admitted to the neonatal intensive care unit with
jaundice, hypotonia and convulsive phenomena during
hypoglycemia and fed via nasogastric tube. She was dis-
charged after 36 days. Cerebral CT Scan and brain ultra-
sound at birth were normal. At the age of 9 months, she
suffered from two episodes of pneumonia. Early motor
milestones were severely delayed: she acquired the
sitting position at the age of 3.5 years and crawled at the
age of 6 years. Her language was limited to rare vocaliza-
tions and never developed further. At the age of 3 years,
she experienced epileptic seizures characterized by im-
pairment of consciousness and head hypotonia, initially
treated with Phenobarbital and subsequently with So-
dium Valproate plus Nitrazepam achieving a completely
seizure-free period until the age of 16 years when sei-
zures, hemiclonic during wakefulness (right side) and
tonic during sleep, recurred. At the age of 16 years, her
height was 150 cm (<3rd centile), weight 28 kg (<3rd
centile) and head circumference 52 cm (3rd centile). At
the same age, EEG showed epileptiform abnormalities,
more frequently on fronto-temporal areas of the left
hemisphere. A tonic seizure was recorded during poly-
somnography at 20 years of age. (Fig. 2a).
The subsequent increases in dosage of both Sodium
Valproate and Clobazam led to the disappearance of the
phenomena during wakefulness. Tonic seizures during
Fig. 1 Photographs of the patient at the age of 9 months (a) 2 years: lateral (b) and frontal views (c) 5 years (d) 13 years (e) and 26 years (f, g, h).
Note the long face, anteverted nares, hypertelorism, open-tended mouth and myopatic face (a-h), abnormal dentition (oversized and overlapping
incisors) and gum hypertrophy (f-h)
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Fig. 2 (See legend on next page.)
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sleep recurred with monthly frequency during her life.
At the age of 26 years, EEG record showed irregular
background activity characterized by abnormalities and
spike-wave complexes, more evident during drowsiness
and sleep (Fig. 2b). At the age of 17 years, she showed
severe scoliosis followed by reduced thorax expansion
and dysventilation with respiratory insufficiency. Her
pubertal development at the age of 17 years was M2
P2; first menses begun at the age of 19 years but then
she presented amenorrhea. During her entire life she
suffered from episodes of gastro-esophageal reflux
and dysphagia. After percutaneous endoscopic gas-
trostomy (PEG) placement at the age of 19 years, the
frequency of respiratory infections (ab ingestis pneu-
monia) decreased and she gained weight (8 Kg). On
ophthalmological examination, convergent strabismus
was detected.
Facial dymorphisms consisted of dolichocephaly, high
forehead, long face, hypertelorism, epicanthic fold, ante-
rverted nares, micrognathia, high-arched palate, abnor-
mal dentition (oversized and overlapping incisors) and
gum hypertrophy, open-tended mouth and myopathic
face (Fig. 1a–f ). She was nonverbal and non-ambulatory.
In particular she presented mild scoliosis, tetraparesis,
pectus excavatum, microsplanchnia, reduced subcutane-
ous fat. Abdomen ultrasound scan, spinal X-ray, ECG,
(See figure on previous page.)
Fig. 2 Representative EEG recordings: a Ictal EEG pattern (recorded at the age of 20 years during drowsiness). An EEG flattening closely related to
low-voltage rapid discharge was recorded prevalently on frontal regions. EMG showed deltoid hypertonia. b Intercritical EEG pattern (recorded at
the age of 26 years during drowsiness). The record shows irregular background activity. Slow abnormalities and spike-waves complexes, prevalent
on anterior regions, were more evident during drowsiness and sleep
Fig. 3 Schematic representation of our patient’s deletion compared with previously reported patients. Top. The screenshot spans 2.5 megabases
of chromosome 5q13.2-q13.3. UCSC genes (GRCh37/hg19) are shown. Middle. Brown bars indicate de novo deletion of patients reported in the
literature that have been characterised by molecular cytogenetics. Our case is represented by a red bar. The light red box indicates the common
deleted region of ~101 Kb among patients sharing the 5q31.3 microdeletion syndrome phenotype. Bottom. Magnified view of breakpoint boundaries
detected by array-CGH analysis using a 180 k Agilent kit. The deleted regions aligned with the UCSC map (hg19) are shaded in red
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Auditory Brain Responses (ABR) and brain MRI were nor-
mal. The patient died of respiratory distress at 26 years.
In the absence of any etiological diagnosis, array-CGH
(Agilent Human Genome CGH Microarray Kit 180 k)
analysis revealed a copy number loss of ~360 kb at
5q31.2q31.3 (Fig. 3). No additional rare copy number
changes were detected in her genome. The deleted gen-
omic region, according to the GRCh37/hg19, included
PURA (located in chromosomal region 5q31.2), IGIP
and CYSTM1 (both located at 5q31.3), while the prox-
imal and distal deletion breakpoint encompassed neure-
gulin 2 (NRG2, located at 5q31.2) and prefoldin subunit
1 (PFDN1, located at 5q31.3) genes, respectively (Fig. 3).
Real-time quantitative PCR (qPCR) assays, performed on
DNA from the patient and her parents, demonstrated
that 5q31.2q31.3 deletion originated de novo (data not




To date at least seven affected children carrying a
5q31.2q31.3 deletion, varying in size from 2.6 to 5 Mb,
have been reported [1–4]. The present patient, aged
26 years, is the oldest reported individual with the smallest
5q31.2q31.3 microdeletion of 360 kb (Fig. 3). The minimal
critical region of overlap between all published cases [1–4],
including the present one, is around ~101 kb and spans
three genes: PURA, IGIP, CYSTM1 [3] (Fig. 3). While the
function of IGIP and CYSTM1 is still unknown, PURA has
been proposed earlier as a candidate gene [1], since it en-
codes Pur-α, a highly conserved multifunctional protein
that has an important role in normal postnatal brain devel-
opment in animal models [6, 7].
In addition, de novo heterozygous PURA mutations, in-
cluding missense and truncating mutations, were recently
identified in several subjects with the neurodevelopmental
phenotype of 5q31.3 deletion syndrome [5, 8, 9]. Different
mechanisms based on mutation type have been postu-
lated: either a dominant negative effect or functional hap-
loinsufficiency in truncating mutations [8], and a negative
effect on protein function in missense mutations [5].
The clinical history of our patient indeed summarizes
the mainly neurodevelopmental phenotype described in
children with 5q31.3 microdeletion syndrome [1–4]. The
perinatal period was characterized by neonatal hypotonia
associated with severe feeding difficulties and respiratory
distress. In our patient, feeding difficulties were severe
and only percutaneous endoscopic gastrostomy (PEG)
placement allowed her to gain weight and reduce the
frequency of respiratory infections (ab ingestis pneumo-
nia). Almost all reported affected children both with
5q31.2q31.3 deletions [1–4] and PURA mutations [5, 8]
were non-ambulatory at the time of evaluation, as
observed in our patient, who showed a more severe out-
come consisting of tetraparesis at the age of 8 years. Re-
spiratory distress, reported in several paediatric patients
with 5q31.2q31.3 deletion [1–4] or PURA point muta-
tion [5, 8], was complicated in our patient by the add-
itional development of severe scoliosis and thoracic
deformity since age of 15 years.
Recognizable craniofacial features similar to previously
described cases, including dolichocephaly, long face,
hypertelorism, micrognathia, high-arched palate, open-
tended mouth, myopathic face were retained in our
patient (Fig. 1a–f ) highlighting that in 5q31.2q31.3
microdeletion patients facial appearance is an important
diagnostic clue.
In contrast to previous reported patients, our case did
not show any signs of hypomyelination or myelin matur-
ation delay or other anomalies at brain MRI, while an
abnormal EEG [1–5, 8] was documented from birth. Her
EEG findings, initially characterised by global slow back-
ground activity, prompted early treatment with anti-
epileptic medication that allowed to maintain our patient
seizure-free during wakefulness, while tonic seizures
during sleep remained at low frequency until her death.
Interestingly, a recent study on model organism Ceanor-
habditis Elegans has shown that homozygous plp1 mu-
tants were sterile with absence of oocytes, suggesting a
requirement for plp1 in germline differentiation [5]. It
has been proposed that the human PURA ortholog
might have an essential role in both somatic and germ-
line tissues [5]. Since Human PURA is expressed both in
brain and ovarian tissues [5], we hypothesize that PURA
haploinsufficiency may be also associated with the de-
layed pubertal development and amenorrhea observed in
our patient, suggesting that this clinical signs might be a
part of the PURA-related disorder in female patients.
Conclusion
The clinical and molecular findings reported here provide
further evidence that patients with a the 5q31.3 microde-
letion syndrome is a clinically discernible PURA-related
disorder. Our patient exhibited a remarkable deterior-
ation of clinical symptoms starting at the beginning of
adolescence. While epileptic seizures were successfully
treated during her life, feeding problems showed a poor
outcome. Her respiratory problems increased and even-
tually became severe enough to cause her death. This
report, the first long-term follow-up of a patient with
5q31.2q31.2 microdeletion involving PURA, will help to
define the syndrome’s clinical evolution and complica-
tions, and suggests that a long term neurological and
EEG follow-up, as well as feeding and respiratory care,
will help to improve the quality of life of patients with
this condition.
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Material and methods
Array-CGH and quantitative (qPCR) analysis
DNA was prepared from peripheral blood using stand-
ard procedures and obtained after informed consent.
Array-CGH analysis was performed using the Agilent
array 180 K (Agilent Technologies) according to the
manufacturer’s protocol. Data analysis was performed
using Agilent Cytogenomics Ed 2.5.8.1. Oligo positions
are referred to the UCSC Genome Browser (Feb 2009
assembly, hg19).
Real-time quantitative PCR (qPCR) assays was performed
on DNA from the patient and her parents using SYBR
Green and analysed on an ABI PRISM 7900HT sequence
detection system (Applied Biosystems, Foster City, CA).
Probe locations were: RT1, chr5:139419393–139419453
(hg19) and RT2, chr5:139619433–139619490 (hg19).
Consent
Written informed consent was obtained from patient’s
parents for the publication of this report and any accom-
panying images.
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